New Drugs and Regulation · eu
Baxdrostat receives EMA committee recommendation for approval for inadequately controlled hypertension
Baxdrostat has moved a step closer to EU market authorization for adults whose blood pressure remains inadequately controlled despite taking at least two antihypertensive medicines. Alongside its blood pressure benefits, the risk of hyperkalemia and the remaining approval process define the significance of this development.
For people whose blood pressure remains inadequately controlled despite taking multiple antihypertensive medicines, a new treatment option is crossing a regulatory threshold. On November 12, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Baxfendy, which contains baxdrostat, recommending approval for adults whose arterial hypertension remains inadequately controlled despite treatment with at least two antihypertensive medicines. The final marketing authorization decision remains with the European Commission.
Baxdrostat is a selective aldosterone synthase inhibitor that acts on blood pressure regulation by intervening in hormone production. Aldosterone causes the kidneys to retain sodium and water, increasing blood volume, and also directly affects vascular function. Inhibiting its synthesis is how this medicine lowers blood pressure. EMA information lists the formulations as 1 mg and 2 mg film-coated tablets.
The evidence supporting the recommendation comes from randomized, double-blind, placebo-controlled studies. According to the EMA, baxdrostat produced clinically meaningful and statistically significant reductions in systolic and diastolic blood pressure in patients whose blood pressure remained uncontrolled while taking at least two antihypertensive medicines. However, the currently available public summary of the positive opinion does not specify the magnitude of the reductions, trial enrollment, or complete follow-up results. This summary alone is insufficient to determine its advantages over other add-on therapies, and the blood pressure results cannot be directly equated with a proven reduction in cardiovascular events.
Safety is another aspect of understanding this development. The EMA lists hyperkalemia as baxdrostat’s most common side effect, but the summary does not provide its incidence or a breakdown by severity. More complete conditions of use and safety information will be published in the summary of product characteristics after the European Commission grants marketing authorization.
Baxfendy was one of seven medicines recommended for approval by the CHMP at its November 9–12 meeting. Ireland’s Health Products Regulatory Authority (HPRA) confirmed that three were new medicines: Baxfendy, Aumseqa (aumolertinib) for non-small cell lung cancer, and Zybrivo (sintilimab) for non-squamous non-small cell lung cancer in adults. The other four were two insulin aspart biosimilars and two generic medicines, meaning the seven recommendations covered different types of medicine applications.
The same meeting also issued positive opinions on extensions of indications for 11 existing medicines. This is a different regulatory process from applications for new medicines: the former assesses whether authorized medicines can be used in new patient populations or disease settings, while the latter reviews whether products can receive marketing authorization. Both types of decisions form part of this month’s review outcomes, but the conditions of use for each medicine must still be considered individually.
The process from scientific review to patients’ actual access to a medicine is not yet complete. The HPRA explains that the CHMP evaluates quality, safety, and efficacy and issues opinions, while the European Commission is the authority that grants centralized marketing authorizations. For Baxfendy, the immediate development is a positive review conclusion. Formal approval, local availability, and pricing and reimbursement arrangements remain separate issues to be addressed subsequently.